Search results
Showing 91 to 105 of 115 results for bladder cancer
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Interventional procedures, IPG235 - Issued: October 2007 --> This guidance has been updated and replaced by NICE interventional procedures guidance 628.
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)
We have moved interventional procedures guidance 638 to become HealthTech guidance 499. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)
We have moved interventional procedures guidance 656 to become HealthTech guidance 522. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)
We have moved interventional procedures guidance 628 to become HealthTech guidance 487. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
In development Reference number: GID-TA11556 Expected publication date: TBC
In development Reference number: GID-TA11884 Expected publication date: TBC
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
In development Reference number: GID-TA11137 Expected publication date: TBC
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
Discontinued Reference number: GID-DT14
In development Reference number: GID-TA11654 Expected publication date: TBC
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.